Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

NCT02036515 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

464

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ertugliflozin 5 mg
DRUG: Ertugliflozin 15 mg
DRUG: Placebo for ertugliflozin 5 mg
DRUG: Metformin
DRUG: Sitagliptin
DRUG: Glimepiride
BIOLOGICAL: Insulin
DRUG: Placebo for ertugliflozin 10 mg

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]